Reacción a "A patient has been in remission from cancer for 18 years after CAR-T treatment as a child, the longest period ever described"

It is a very interesting study that focuses on long-term survival. It is a very important study, given that there is still not much evidence on this type of long-term survivor. Although it includes few patients, this does not detract from its interest and hopefully it will be the first of many. 

Although this type of first-generation CAR-T is no longer used, it provides data on long survivors, from which we still have much to learn. I don't see major implications beyond knowledge generation, but it is true that it does appear that long survivors have had longer persistence of CAR-Ts. This is one of the challenges of CAR-Ts, persistence, although researchers have not probed why. 

The most important limitation is the very small number of patients, as there remains the doubt that it may be something intrinsic to the patient in response to this immunotherapy. In any case, this type of study is complicated, so it has added value.